The University of Arizona Cancer Center Lymphoma Program combines excellent patient care with research and is dedicated to finding a cure for all lymphomas and CLL.

- Established a comprehensive multidisciplinary clinical treatment team with expertise in combined modality treatments, high-dose treatments with bone marrow/stem cell transplant, monoclonal antibody treatment (including radioimmunotherapy), and investigational new therapies for recurrent/resistant disease.
- Includes National Cancer Institute, American Cancer Society and philanthropy funding for the Lymphoma Consortium, Central Lymphoma Tumor Repository and Immunophenotyping, Lymphoma Translational Medicine Committee, as well as research on lymphoma gene expression signatures and support for translational research objectives of specific clinical trials.

The Medical Oncology section of the Lymphoma Program offers:

- Combined modality treatments, high-dose treatments with bone marrow/stem cell transplants and monoclonal antibody treatment
- Clinical trials that bring the most active new agents to our patients.
- Laboratory research on the biology of lymphomas and CLL
- The exploration of new strategies to prevent, diagnose and cure lymphomas and CLL

Lymphoma Program accomplishments over the last three decades:

- The University of Arizona Cancer Center, along with the James P. Wilmot Cancer Center at the University of Rochester, is home to one of five Specialized Programs of Research Excellence in Lymphoma, funded by the National Cancer Institute.
- Developed state-of-the-art diagnostic capabilities benefiting patients referred to the Cancer Center or treated throughout Arizona.
- Identified optimal treatment for localized (limited) non-Hodgkin lymphoma.
- Established the benchmark for treatment of advanced aggressive non-Hodgkin lymphoma.
- Designed and participated in studies showing a 70% reduction in death for patients with follicular non-Hodgkin lymphoma.
- Made seminal contributions to the Lymphoma/Leukemia Molecular Profiling Project.
- Gained insight as to why treatment fails (tumor cell characteristics, drug resistance).
- Demonstrated that drug resistance can be reversed.
- Developed automated systems for laboratory evaluation of lymphomas.
- Investigations of new ways to detect and monitor cancer (biomarkers).
Current areas of research are focused on:

- Determining the relationship of specific tumor gene expression patterns to treatment outcome.
- Understanding the contribution of the intracellular redox environment to lymphoma biology and treatment response.
- Understanding how the tumor microenvironment and host response affect patient survival.
- Identifying new therapies both in B and T-cell lymphomas targeted to take advantage of unique tumor characteristics.

Medical Oncology
Daniel O. Persky, MD
Soham Puvvada, MD
Jonathan Schatz, MD

Pathology
Deborah Fuchs, MD
Maria Proytcheva, MD
Lisa Rimsza, MD
Catherine Spier, MD

Radiation Oncology
Baldassarre “Dino” Stea, MD, PhD, FASTRO
Victor Gonzalez, MD

Surgical Oncology
Farid Gharagozloo, MD, FACS
James A. Warneke, MD, FACS

Dermatologic Oncology
Clara Curiel, MD

Medical Imaging
Philip Kuo, MD, PhD
Ryan Avery, MD

Appointments: UACC–North Campus (520) 694-CURE (2873)

Web: www.arizonacancercenter.org